SS Innovations International, Inc.

SSII
About the company

SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE), Nepal, and internationally. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems.

Country: United StatesPrice: $1.66Market Cap: $332.8M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2089 (Top 67.5%)PASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-10

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 4✗ 31▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/11 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/11 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-312.0%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-19.3% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-12.1M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-23.3%
      ✗Lynch> 15%
      EBIT / Enterprise Value-2.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-2.5%, ROC=-28.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-16.34%
      ✗PiotroskiROA > 0
      ROA Change YoY-45.18% -> -16.34% (delta: +28.85%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-24.98%, ROA=-16.34%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY40.9% -> 46.0%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-15.6%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-23.3%
      ✗Dreman> 12%
      Margin of SafetyP/B=8.4x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-93.3% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-16.2%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-23.3%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-345.1% (2023) -> -19.3% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 12.3% -> 46.0%, operating margin -345.1% -> -19.3%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-3.74%; #3751/6340 (top 59.2%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+25.75%; #1669/3702 (top 45.1%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-23.28%; #3762/5226 (top 72.0%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-1.2218; #5330/5884 (top 90.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio8.4x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-2.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-2.5%, ROC=-28.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share8.4x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-4.6%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-6.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=8.4x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($1.66)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-3.74%; #3751/6340 (top 59.2%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.1605; #4406/6449 (top 68.3%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share8.44x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.1575; #4008/5247 (top 76.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-6.67%; #3074/4519 (top 68.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-61.40%; #5434/6202 (top 87.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✗ 12▾

      All 10 investors flag SSII's cash flow

      Free Cash Flow Proxy$-12.1M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-22.2M
      ✗LynchPositive and growing
      Operating Cash Flow$-18.5M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-24.98%, ROA=-16.34%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-6.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/4 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-6.9%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/10 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-22.2M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-6.67%; #3074/4519 (top 68.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 67.2% vs Rev: 105.7%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.03 (2016) -> $-0.06 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth251.5%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 12.3% -> 46.0%, operating margin -345.1% -> -19.3%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts7% pass✓ 1✗ 14▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2089✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag SSII's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.24
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-30.2x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Efficiency38% pass✓ 4✗ 7▾

      5 of 8 flag SSII's efficiency — Buffett, Greenblatt, Munger +2 more

      Current Ratio2.24
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-80.7%
      ✗Buffett> 10%
      ROIC - WACC-90.7%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-28.8%
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.29 -> 1.86
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.49x -> 0.57x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities2.24
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-79.2%; FY2024: ROIC=-71.7%; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/2 years above 12% (latest -71.7%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Small Cap($332.8M)
    Revenue: $42.5M+105.7% YoY
    Net Income: $12.1M+36.7% YoY

    Financial Snapshot

    Operating Margin-19.3%
    Return on Equity-31.7%
    Debt / Equity--
    Current Ratio1.86
    EPS (Diluted)$-0.06
    Shares Retired−13.3% / −13.8% 2y

    Shareholder Return

    Fiscal 2025

    Issued 13.3% of shares last year, 13.8% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: interest expense, operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, depreciation amortization.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: interest expense, operating cash flow.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-10
    FY 2024
    Sources
    • 10-K · 2025-04-15
    FY 2023
    Sources
    • 10-K · 2024-03-22
    FY 2022
    Sources
    • 10-K · 2023-03-31
    FY 2021
    Sources
    • 10-K · 2023-03-31
    Market Cap$332.8Mcurrent----$822.1Mest.$1.6Best.$54.6Mest.----
    Revenue$52.4M$13.9M↑39%$11.1M↑117%$42.5M↑106%$20.6M↑251%$5.9M↑309%$1.4M--
    Operating Income-$8.5M↑56%-$2.3M↓2441%-$3.6M↑39%-$8.2M↑57%-$19.0M↑6%-$20.3M↓585%-$3.0M--
    Net Income-$12.4M↑36%-$2.7M↓937%-$3.6M↑37%-$12.1M↑37%-$19.2M↑8%-$20.9M↓550%-$3.2M↓117%-$1.5M
    EPS (Diluted)--$-0.01$-0.02↑33%$-0.06↑45%$-0.11↑31%$-0.16↓220%$-0.05$-0.05
    Gross Margin47.6%50.9%↓14%48.0%↑126%46.0%↑12%40.9%↑231%12.3%↑193%4.2%—
    Operating Margin-16.2%-16.3%↓1780%-32.8%↑72%-19.3%↑79%-91.9%↑73%-345.1%↓68%-206.0%—
    ROE-23.3%↑50%——-31.7%↑78%-142.3%↓34%-105.9%↓188%120.0%↑147%-253.5%
    Total Debt--------$7.5M↑1360%$510.2K↓14%$589.9K↑307%$145.0K
    Shareholders' Equity$53.4M↑27%$53.4M↑27%$54.5M↑34%$38.2M↑184%$13.5M↓32%$19.7M↑836%-$2.7M↓557%$585.6K
    Current Ratio2.24↓13%2.24↓13%2.54↓20%1.86↑45%1.29↓49%2.53↑380%0.53↓63%1.42
    Debt / Equity————0.55↑2040%0.03↑112%-0.22↓189%0.25
    Operating Cash Flow-$15.5M↑8%-$4.2M↓23%-$2.3M↑62%-$18.5M↓95%-$9.5M↑38%-$15.4M↓156%-$6.0M↓1551%-$363.0K
    Free Cash Flow-----$2.4M↑66%-$22.2M↓118%-$10.2M↑36%-$15.8M↓154%-$6.2M--

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    SSII vs Peers — Financial Grading

    Revenue$42.5MBottom 25%
    Net Income$12.1MBottom 25%
    ROE-31.7%Bottom 25%
    D/E—
    Op. Margin-19.3%Bottom 25%
    Curr. Ratio1.86Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11